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Abstract 
O-Desmethylangolensin (O-DMA) is a product of anaerobic intestinal bacterial metabolism of 
the isoflavone daidzein, which is found mainly in soy foods. Because of its structural 
similarity to natural estrogen, it was found to have a strong binding affinity to human estrogen 
receptor β, thus explaining its anticarcinogenic activity among other biological actions. 
Because of its biological importance, the main aim of this study is to propose a synthetic route 
using (R,R)-(-)-Pseudoephedrine as chiral auxiliary to synthesize enantiopure (R)-(-)-O-DMA. 
Pseudoephedrine has been previously found to be an excellent chiral auxiliary; its amide is 
stable, easily prepared and its enolate is highly reactive and can undergo many useful 
transformations including alkylation reactions.  
4-Hydroxyphenylacetic acid was used as starting material. Diastereoselective α-methylation of 
the pseudoephedrine amide was done using LDA in THF with subsequent addition of methyl 
iodide. The method was found successful; however, the yield (55%) and % ee (4.5%) were 
low, thus further adjustments are needed. 
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1 Introduction 
1.1 O-desmethylangolensin 
1.1.1 Sources 
Isoflavones and lignans are plant-derived secondary metabolites, which are frequently 
consumed in the diet and are believed to benefit human health. Whereas lignans are found in 
fiber-rich foods such as: whole grains and seeds (flaxseed, linseed and sesame seeds), the most 
common sources of dietary isoflavones are soybeans and their products including soy flour, 
soy milk, miso, tofu and tempeh. Isoflavones and lignans as well as their metabolites belong to 
a class of compounds referred to as phytoestrogens, which from the name implies their ability 
to bind to estrogen receptors considering their structural similarity to natural 17β-estradiol 4.1,2 
O-Desmethylangolensin 3 (O-DMA) and equol 2, first identified in human urine in the 1980s, 
were later recognized to be the intestinal bacterial metabolic products of the soy isoflavone 
daidzein 1.
3
 Figure 1 shows the structures of 17β-estradiol 1, the isoflavone daidzein 2 and its 
major metabolites, equol 3 and O-DMA 4. 
   
Figure 1: Structures of 17β-estradiol (E2), daidzein, equol and O-DMA.
3
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1.1.2 Production and metabolism 
Modification of the soy isoflavones by the intestinal bacteria produces metabolites that might 
have a more potent, or even different, biological actions than their compounds. Thus, the 
metabolic fate of these isoflavones directly affects their biological activity.
4,5
 As mentioned 
above, the precursor of O-DMA and equol is daidzein 2, found in fermented soy foods, or the 
glycoside form daidzin, found in unfermented soy foods. After ingestion, daidzin can be 
hydrolyzed in the small intestine by β-glycosidase to form the aglycone daidzein 2, which is 
further metabolized by anaerobic bacteria in the large intestine into dihydrodaidzein.
3,7
 Other 
intestinal bacteria then reduce this compound to equol 3 or cause ring cleavage to form O-
DMA 4 (Figure 2). O-DMA can then be absorbed and conjugated to the glucuronide/sulfate in 
the liver/intestinal mucosa to make it water soluble, which can then be released from the liver 
into the circulation and finally excreted by the kidneys into the urine. Also, a part can be 
released by the liver into the bile, where it undergoes enterohepatic circulation (Figure 3).
3
  
 
Figure 2: Metabolism of daidzein to equol and O-DMA.
4
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Figure 3: Production and metabolic fate of O-DMA.
3
 
Considering the fact that equol-producing bacteria are distinct from O-DMA-producing 
bateria
3
, soy isoflavones bacterial metabolism differs among individuals depending on the type 
of intestinal bacteria that exist in the GIT.
4
 80-90% of humans possess bacteria that are 
capable of producing O-DMA
4,6
 and are referred to as O-DMA-producers
3
, while only 30-
50% possess equol-producing bacteria
4
 and are referred to as equol-producers.
3
  
Regarding O-DMA-producing bacteria, very few strains were identified to be able to cleave 
the C-ring of daidzein, which include Eubacterium ramulus, Eubacterium ramulus Julong 601 
and Clostridium HGH 136.
7,8
 E. ramulus represents approximately 0.16% of the total fecal 
flora, which is a comparable amount to that of E. coli, thus it can be considered as one of the 
major bacteria in the human GIT able to degrade isoflavonoids, though it was found that E. 
ramulus was not able to further metabolize O-DMA.
5
 Recently, a novel strain SY8519 
belonging to Clostridium rRNA cluster XIVa was isolated from human feces
6
 and its complete 
genomic sequence was determined.
9
 Not only was it able to metabolize daidzein, but also a 
variety of other polyphenols.
6
 However, the genes associated with daidzein metabolism could 
not be predicted.
9
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1.1.3 Biological properties 
Isoflavones and their metabolites, including O-DMA, have been observed to exert several 
biological actions in in vitro and in animal studies.
3,7
 Having a diphenolic structural similarity 
to estradiol (E2), they have been established to have a weak estrogenic or antiestrogenic 
activity.
10
 Compared to the precursor isoflavone daidzein, other isoflavones and their 
metabolites, O-DMA demonstrated the strongest binding activity to hER β, as strong as E2, 
but a weaker binding activity to hER α.13 Furthermore,  it showed antiproliferative effects on 
human hepatocellular carcinoma (HCC) Hep3B cells with a lower IC50 value than that of 
daidzein. The mechanism of action appeared to occur via cell cycle arrest at the G2/M phase 
and subsequent apoptosis. This occurred through reduction of CDK1, downregulation of Bcl-2 
and upregulation of Bax, which lead to the mitochondrial release of cytochrome c and 
caspase-3 activation inducing apoptosis.
11
 Another recent study supported these results by 
showing that O-DMA caused inhibition of cell proliferation and induction of apoptosis of 
human breast cancer MCF-7 cells through cell cycle arrest at G1/S and G2/M phases as well as 
increasing and decreasing the levels of the cell cycle regulators CDK4/6-cyclin D and CDK1-
cyclin B complexes respectively, affecting their interactions.
12
 All these findings confirm the 
hypothesis of O-DMA being a promising anticancer drug candidate.
11
 
On a related aspect, a study conducted on 55 postmenopausal women demonstrated that the 
percent mammographic density, which is an intermediate marker of breast cancer risk, was 
69% greater in O-DMA producers than non-producers, whilst 39% lower in equol producers 
than non-producers. Further adjustment for selected circulating hormone concentrations (FSH, 
free testosterone) suggested that these endogenous hormones are responsible for this 
relationship between mammographic density and O-DMA-producer phenotype. Nevertheless, 
the exact mechanism by which daidzein metabolites, equol and O-DMA, could affect the 
mammographic density is still not known. Though there are several hypotheses, including the 
binding capability of equol and O-DMA to estrogen receptors, exogenous and/or genetic 
factors influencing the intestinal environment allowing daidzein-metabolizing bacteria to 
flourish. This study had a serious limitation of utilizing only one sample of a small size, thus 
these results should be confirmed with a larger sample size and more diverse 
specifications.
14,15
  
13 
 
Ishimi et al. studied the effects of O-DMA on bone and lipid metabolism in OVX mice. They 
observed that bone loss was not affected as well as only weak inhibition of osteoclast 
formation in vitro. However, O-DMA did influence the plasma lipid profile, where decreased 
levels of TG, TC
18
 and LDL and increased levels of HDL
17
 were observed in estrogen-
deficient mice
18
 and postmenopausal women.
17
 These effects could be due to ER binding in 
addition to inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, 
which is involved in cholesterol biosynthesis
18
, though the exact mechanism should be further 
studied. 
1.1.4 Chirality 
Equol has been much studied and it was identified that the (S)-(-) enantiomer 3a is the major 
form produced during intestinal bacterial metabolism of daidzein.
19,20
 However, only recently, 
a couple of papers were published identifying the main enantiomeric form of the other 
optically active daidzein metabolite to be (R)-(-)-O-DMA 4a.
7,21
 Figure 4 shows the structures 
of the major enantiomeric forms of equol and O-DMA found in human plasma and urine post 
intestinal bacterial metabolism of daidzein. Time-Dependent Density-Functional Theory 
(TDDFT) calculations, together with Circular Dichroism (CD) spectra of pure O-DMA 
enantiomers in ethanol were used to establish the absolute configuration and the major form’s 
optical rotation     
   was also measured and found to have a negative value (-135.8º).
7,21
 
 
Figure 4: Structures of (S)-(-)-Equol and (R)-(-)-O-DMA. 
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1.1.5 Synthesis 
There are various ways to obtain racemic O-DMA 4. In literature, it was either provided by 
Plantech (Reading, UK)
7
 or more commonly synthesized by a one-step Friedel-Crafts 
acylation of resorcinol 6 with racemic 2-(4-hydroxyphenyl)-propionic acid 7 in BF3.Et2O 
(Figure 5).
21-23
 A study conducted to investigate the anticancer effects of O-DMA prepared it 
using a different multistep synthetic route (Figure 6).
11
 Both protocols claimed to produce 
similar yields of approximately 80-90%, thus the Friedel-Crafts acylation seems to be much 
simpler, faster and cheaper. 
 
Figure 5: Synthesis of racemic O-DMA by Friedel-Crafts acylation (80% yield
22,23
). 
 
Figure 6: Alternative longer route for racemic O-DMA synthesis (90% yield
11
). 
To date, the sole method used to obtain enantiopure O-DMA is through preparative chiral 
HPLC separation. A Sumi-chiral column, OA 7000 (8x250mm, Sumika Chemical Ltd., Osaka, 
Japan) is used and separation is done using isocratic 40% acetonitrile in water.
7,8,21
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1.2 Asymmetric synthesis of 2-phenylpropanoic acid 
Given that the chirality of O-DMA 4a exists at C-2, which originates from the acid component 
7a of the Friedel-Crafts acylation, it was essential to review the different methods reported in 
literature for the synthesis of enantiopure 2-arylpropanoic acid. Aside from the use of a chiral 
auxiliary for asymmetric α-alkylation, which will be explained further in the next chapter, 
various catalytic approaches were studied for the asymmetric synthesis of 2-phenylpropanoic 
acid 8 (Figure 7) as a model compound. The most common method is homogenous catalysis 
using transition metals coordinated with chiral ligands, but also some electrochemical and 
enzymatic catalysis were reported.  
 
Figure 7: Structures of (R)-(-)-O-DMA, its acid component ((R)-(-)-2-(4-
hydroxyphenyl)propionic acid) and (R)-2-phenylpropionic acid. 
  1.2.1 Asymmetric hydrogenation 
One of the most studied reactions of homogenous catalysis is the asymmetric hydrogenation of 
olefins using transition metal complexes, most commonly of Ru(II)
24,25,27,28,32
, Ir(I)
29,31
 and 
Rh(I).
26,30,33
 This can be utilized for the conversion of 2-phenylacrylic acid 9 to enantiopure 
(R)-2-phenylpropanoic acid 8 (Figure 8).  
 
Figure 8: Asymmetric hydrogenation of 2-phenylacrylic acid. 
For the past 20 years, several chiral phosphine ligands have been developed and their reaction 
conditions have been studied to improve the results. The highest yields (>90 %) and % ee (96-
16 
 
97%) were achieved using chiral ligands of cyclic nature; P-stereogenic phosphine ligands 
with Rh(I)
30
 16, 17 (entries 7 and 8, Table 1), SpinPHOX ligands
29
 15 (entry 6, Table 1) and 
spiro aminophosphine ligands
31
 with Ir(I) 18 (entry 9, Table 1). Also, attempts to improve the 
product separation and catalyst recovery have been investigated, which achieved 86-92% ee. 
Examples include the use of room temperature molten salts, as BMI.BF4
24
, (entry 1, Table 1) 
or liquid PEGs
28
 (entry 5, Table 1) in the solvent system and dendritic chiral ligands
32
 19 
(entry 10, Table 1) to immobilize the catalytic transition metal complex. Other types of chiral 
phosphine ligands were employed such as: biheteroaromatic (-)-tetra-Me-BITIOP
2
 11 (entry 2, 
Table 1), ferrocene-based 1,3-bis(phosphanes) with planar chirality
26
 12 (entry 3, table) and 
monodentate secondary phosphine oxide
33
 (SPO) 20 (entry 11, Table 1). Table 1 summarizes 
some of the transition metal complexes used as catalysts for the asymmetric hydrogenation of 
2-phenylacrylic acid along with the solvent(s) used, reaction conditions [S/C 
(substrate/catalyst ratio), PH2 (H2 pressure), T (temperature)], % yield, % ee and the 
conformation (conf.) of the major enantiomer formed. Figure 9 shows the structures of the 
transition metal complexes and/or ligands listed in Table 1.  
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Table 1: Transition metal complexes used for the asymmetric hydrogenation of 2-
phenylacrylic acid 
Entry TM complex 
Solvent(s) 
(ratio) 
S/C PH2 (atm) 
T 
(ºC) 
Yield 
(%) 
% ee 
(conf.) 
1 Ru-(R)-BINAP
24
 10 MeOH/BMI.BF4 40 25 rt - 86 (R) 
2 
(-)-[(TetraMe-
BITIOP)Ru Bis(2-
methallyl)]
25
 11 
MeOH 160 50 20 - 94 (R) 
3 
[Rh(cod)Fe/bis(phosph
ane)]PF6
26
 12 
MeOH - 1 - 90 83 (R) 
4 
(R,R)-TsDPEN-Ru(II)
27
 
13 
DCM 100 -  30 97 7 (R) 
5 
PEG supported Ru-(R)-
BINAP
28
 14 
PEG-600/MeOH 
(1:2) 
100 50 20 - 
92.4 
(R) 
6 
Ir-(R,S)-SpinPHOX
29
 
15 
MeOH 100 30 50 - 96 (R) 
7 
[Rh((R,R)-cPen-SMS-
phos)(MeOH)2]BF4
30
 
16 
MeOH 100 Ambient rt >90 
96.4 
(R) 
8 
[Rh((R,R)-Cy-SMS-
phos)(MeOH)2]BF4
30
 
17
 
MeOH 100 Ambient rt >90 
97.1 
(S) 
9 
Ir complex with chiral 
spiro aminophosphine 
ligands
31
 18 
MeOH  1000 
6 (15min) 
Ambient (4h) 
45 
97 
95 
98 (R) 
98 (R) 
10 
[Ru(p-cymene)Cl2]2/ 
dendritic BINAP
32
 19 
MeOH/toluene 
(1:1) 
- 80 20 - 86 (R) 
11 
[Rh(μ-Cl)(cod)]2/(S,S)-
SPO
33
 20 
Dioxane 200 30 rt - 93 (R) 
 
18 
 
 
Figure 9: Structures of the transition metal complexes or ligands listed in Table 1 
19 
 
 
Figure 9 cont.: Structures of the transition metal complexes or ligands listed in Table 1 
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  1.2.2 Asymmetric hydrocarboxylation 
Another type of functionalization of olefins is asymmetric hydrocarboxylation, which can be 
done using homogenous catalysis, where, as a model relevant to the purpose of this work, 
styrene 21 can be converted to enantiopure (R)-2-phenylpropanoic acid 8 (Figure 10).
34-38
 
 
 
Figure 10: Asymmetric hydrocarboxylation of styrene. 
In literature, there are a few approaches to which how this can be achieved. The most direct 
route is the use of CO and H2O in the presence of a transition metal chiral complex. However, 
the linear carboxylic acid product 23 will be partly formed along with the desired branched 
product 8 (Figure 11). Earlier research using Pd with chiral sulfonated diphosphine ligands, 
(S,S)-BDPPTS 25 and (R,R)-CBDTS 26, yielded low branched/linear (b/l) acid products ratio 
(0.52 and 0.41 respectively) with a %ee of only 32% (R) and 14% (S) respectively (entries 5 
and 6, Table 2).
36
 Further studies using dipalladium complexes with chiral phanephos ligands 
27
37
 and 28
38
 improved the b/l ratio in favor of the branched product with approximately 80% 
ee (R) (entries 7 and 8, Table 2), where in the latter case, MeOH was used instead of H2O and 
the branched product is formed almost exclusively (b/l >100).
38
 
 
Figure 11: Asymmetric hydrocarboxylation of styrene using CO and H2O.
34-38
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An alternative strategy is to separate the metal hydride addition step creating the stereocenter 
followed by the stereospecific C-C bond formation. In this case, a stable carbon surrogate 
(such as: boron), which can be easily replaced by carbon in a stereospecific manner, is 
required. Asymmetric catalytic hydroboration of styrene followed by homologation with 
LiCHCl2 (generated by deprotonation of DCM with n-BuLi) and oxidation with NaClO2 
(Figure 12) was found to be successful in producing (R)-2-phenylpropanoic acid 8 with 
moderate yields (45-87%) and 93-95% ee (entries 1-4, Table 2).
34,35
  
 
Figure 12: 2-Step asymmetric hydrocarboxylation of styrene.
34,35
 
Asymmetric catalytic hydroformylation of styrene with CO and H2 followed by oxidation of 
the aldehyde moiety into a carboxylic acid can also be another synthetic scheme. A Rh(I) 
complex with glucopyranoside-based diphosphite ligand 29 was reported to yield 2.85 b/l ratio 
and 41% ee (entry 9, Table 2).
39
 Table 2 summarizes some of the transition metal complexes 
used as catalysts for the asymmetric hydrocarboxylation of styrene along with the catalyst and 
reagents used, b/l ratio, % yield, % ee and the conformation (conf.) of the major enantiomer 
formed. Figure 13 shows the structures of the transition metal complexes and/or ligands listed 
in Table 2.  
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Table 2: Transition metal complexes used for the asymmetric hydrocarboxylation of styrene 
Entry Catalyst  Reagent b/l Yield (%) % ee (conf.) 
1 
[Rh(cod)2]BF4/(R)-
BINAP
34
 24 
(RO)2BH - 95 95 (R) 
2  
1. LiCHCl2, ZnCl2 
2. NaClO2 
- 45 95 (R) 
3 
[Rh(cod)2]BF4/(R)-
BINAP
35
 24 
(RO)2BH - 99 93 (R) 
4  
1. LiCHCl2 
2. NaClO2 
- 87 93 (R) 
5 
Pd(OAc)2/(S,S)-
BDPPTS
36
 25 
CO (20 bar), H2O 0.52 - 32 (S) 
6 
Pd(OAc)2/(R,R)-
CBDTS
36
 26 
CO (20 bar), H2O 0.41 - 14 (R) 
7 
Dimetallic Pd/(R)-
phanephos ligands 
complex
37
 27 
CO (30 bar), H2O 1.1 71 80 (R) 
8 
Dimetallic Pd/(R)-
phanephos ligands 
complex
38
 28 
CO (30 bar), MeOH >100 >99 79 (R) 
9 
Rh(acac)(CO)2/(S)-
binaphthol
39
 29 
1. CO (3 bar), H2 
(17 bar) 
2. Jones oxidation 
2.85  41 (S) 
23 
 
 
Figure 13: Structures of the transition metal complexes or ligands listed in Table 2 
  1.2.3 Asymmetric electrocarboxylation 
Aside from homogenous catalysis, the carboxylic acid functional group can also be added 
using electrochemistry. In the past decades, electrochemical reduction of aromatic halides in 
CO2-saturated solutions for the synthesis of their corresponding carboxylic acids has been of 
much interest as an alternative to the use of homogenous catalysis.
40
 However, very few 
studies have been done concerning asymmetric electrocarboxylation. Feroci et al. have been 
successful to synthesize chiral methylmalonic ester
41,42
 and cinnamic acid derivatives.
43
 
Recently, electrochemical asymmetric carboxylation of phenylethyl chloride 30 with CO2 
using chiral Co
II
-(R,R)(salen) 31 (Figure 15) as a catalyst to produce (R)-2-phenylpropionic 
acid 8 was reported (Figure 14).
44
 The best results were of 37% yield and 83% ee (R), which 
were obtained in solvent DMF at the optimum conditions: temperature of 50ºC, charge of 3.0 
Fmol
-1
, substrate concentration of 50 mM, catalyst/substrate ratio of 15 mol%, applied 
potential of (Eapp) of -1.59 V and CO2 pressure (PCO2) of ~ 1 atm (1x10
5
 Pa). They also stated 
that the reason for the low yield values is probably due to reduction of intermediates supported 
24 
 
by the GC-MS detection of unreacted benzyl chloride, 2,3-diphenylbutane, phenylethane and 
styrene. Nevertheless, further research in this asymmetric electrocarboxylation system could 
provide a new synthetic route of enantiopure chiral carboxylic acids from achiral substrates.
44
  
 
Figure 14: Asymmetric electrocarboxylation of phenylethyl chloride.
44
 
 
Figure 15: Structure of the chiral catalyst Co
II
-(R,R)(salen).
44 
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1.3 Asymmetric α-alkylation 
1.3.1 Chiral auxiliary 
Asymmetric α-alkylation of carboxylic acid derivatives is a useful reaction in organic 
synthesis. These α-alkylated derivatives are versatile synthetic intermediates; where the 
carboxylic acid moiety can undergo a variety of transformations. An effective method to 
achieve this transformation is based on the use of a chiral auxiliary. Over the years, a lot of 
work has been done to design new chiral auxiliaries with more efficient yields and better 
optical purities.
52
 
Chiral auxiliary-based asymmetric alkylation of carboxylic acid enolate was first reported by 
Myers et al. in 1976, where oxazoline anions were readily alkylated by a variety of alkyl 
halides and showed high diastereoselectivities.
45
 Evans et al. first described the asymmetric 
alkylation of N-acyl oxazolidinones 32 in 1982 (entry 1, Table 3) (Figure 16). Further 
improvements were done using Ti-enolates 33 instead of Li- or Na-enolates (entry 2, Table 3) 
(Figure 17).
52
 Moreover, S-proline was successfully used as a chiral auxiliary in asymmetric α-
alkylation of phenyl acetic acid to give (R)-2-phenylpropionic acid 8 (    
   = -76º) in 65% 
yield and 80% de of the alkylated intermediate 34a (entry 3, Table 3) (Figure 18).
53
 Several 
camphor-based chiral auxiliaries
52,54
 (Figures 19 and 20) have also been reported for the 
asymmetric α-alkylation of carboxylic acids with high yields and diastereoselectivities (entries 
4 and 5, Table 3). Another very common chiral auxiliary studied for this type of 
transformation is pseudoephedrine; which will be explained in more details later. Table 3 
summarizes the different chiral auxiliaries, aside from pseudoephedrine, explained above 
along with the reaction conditions and results of some of their alkylation reactions. 
 
 Figure 16: Oxazolidinone-based asymmetric alkylation.
52
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 Figure 17: Oxazolidinone-based asymmetric alkylation via Ti-enolates.
52
 
 
   Figure 18: S-proline-based asymmetric alkylation.
53
 
 
 Figure 19: Camphor-based 2-phenylimino-2-oxazolidine chiral auxiliary.
54
 
 
 Figure 20: Camphor-based Oppolzer sultam chiral axiliary.
52
 
 
 
27 
 
Table 3: Chiral auxiliaries used for asymmetric α-alkylation of carboxylic acids 
Entry Chiral auxiliary Base RX/E 
Alkylated 
intermediate 
% de 
1 Oxazolidinone
52
 LDA 
BnBr 
EtI 
32a 
98 
88 
2 Oxazolidinone
52
 TiCl4, i-Pr2NEt BnOCH2Cl 33b >100 
3 (S)-Proline
53
 LiHMDS MeI 34a 80 
4 
2-Phenylimino-2-
oxazolidine
54
 
LiHMDS EtI 35b >99 
5 Oppolzer sultam
52
 NaHMDS BnI 36a 98 
 
1.3.2 Pseudoephedrine as chiral auxiliary 
1.3.2.1 Advantages 
The key advantages of using pseudoephedrine as chiral auxiliary depend mainly on the fact 
that it is inexpensive and easily available in bulk in both enantioforms.
47
 Moreover, they  are 
easily acylated to form their amides, which are usually crystalline
46,48
 and can undergo a 
variety of diastereoselective reactions in a highly efficient manner including alkylation 
reactions using many alkyl halides.
46
 In addition to its synthetic versatility producing 
interesting chiral building blocks with different functional groups
47,49
, the pseudoephedrine 
moiety can be easily removed and recovered without considerable loss providing a further 
benefit of recyclability.
47,50
   
1.3.2.2 Synthesis of pseudoephedrine amides 
Formation of amide bond is a fundamental and established reaction in organic chemistry. N-
acylation of the amino alcohol pseudoephedrine 37 is an example of this transformation. As 
shown in Figure 21 below, the carboxylic acid moiety should be activated in order for the 
acylation reaction to proceed in a high yield. The carboxylic acid derivatives most commonly 
used are anhydrides or acid chlorides. While the carboxylic acid anhydrides can undergo 
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efficient acylation in DCM or THF as solvent and the presence of base is not essential other 
than to fasten the reaction, acylation with carboxylic acid chlorides needs the addition of a 
slight excess of base, such as: Et3N. Nevertheless, they readily react at low temperatures (0 ºC) 
in most organic solvents. If neither the anhydride nor the acid chloride is accessible, mixed 
anhydride from the carboxylic acid, pivaloyl chloride and Et3N was found to be a suitable 
alternative.
46
  
 
Figure 21: N-acylation of pseudoephedrine
46
 
The formed amide products 38 are anhydrous, air-stable and highly crystalline. A small 
amount of N,O-diacylated compound was the only byproduct reported, which can be easily 
separated by direct recrystallization of the crude product or by flash chromatography.
46
  
1.3.2.3 Asymmetric alkylation of pseudoephedrine amides 
As mentioned above, pseudoephedrine amides 34 undergo efficient asymmetric α-alkylation 
reactions using alkyl halides, which can be attributed to the fact that the amide functionality is 
highly reactive and its enolate is a strong chiral nucleophile.
50,51
 There are two options to carry 
out this diastereoselective alkylation reaction: either using excess alkyl halide or excess 
enolate. In the former case, the yield will be dependent on the enolate (limiting reagent) and 
vice versa in the latter case. It has been reported that the yield is slightly higher when the alkyl 
halide is the limiting reagent. However, it is not significant enough and the choice is usually 
based on the availability and the cost of one reagent relative to the other. Enolization is usually 
done by the base, LDA, which is formed by mixing in dry THF n-DIPA with n-BuLi in 
hexanes at -78 ºC. In both cases, reverse addition of starting materials is employed, where the 
pseudoephedrine amide solution is added gradually to a cold suspension of LDA/LiCl to 
produce the enolate followed by addition of the alkylating agent (Figure 22).
46
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Figure 22: Diastereoselective alkylation of pseudoephedrine amides
46 
The reason for adding lithium chloride (LiCl) to the reaction mixture is to speed up the rate of 
alkylation as well as to suppress O-alkylation of the pseudoephedrine secondary alcohol 
group, thus decreasing the amount of byproducts. Myers et al. recommended the addition of 
6.0-7.0 equiv. of LiCl and not less than 4.0 equiv. for optimum reaction rate and yield. They 
also proved that the presence of LiCl does not influence the diastereoselectivity of the 
alkylation reaction. However, it should be taken as a precaution that the LiCl used is 
completely anhydrous because if any water is present, this may lead to quenching the base 
(LDA) and enolization will not be successful.
46
 
Pseudoephedrine amide enolates 34a are highly reactive nucleophiles, therefore they react 
efficiently with primary alkyl halides at a temperature as low as -78 ºC and with high 
diastereoselectivity. The major alkylated product 35 is the result of the electrophilic attack of 
the alkyl halide on the (Z)-enolate from the same face as the methyl group of the 
pseudoephedrine, i.e. the additional alkyl group and the pseudoephedrine methyl group are on 
the same side of the molecule (Figure 23). When using β-branched alkyl halides, they also 
react efficiently, but a higher temperature is needed (23 ºC), which does not cause a problem 
due to the thermal stability of the pseudoephedrine amides.
46
 
 
Figure 23: Pseudoephedrine amide enolate alkylation
46 
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1.3.2.4 Hydrolysis of pseudoephedrine amides 
To form carboxylic acids 36 from the alkylated products 35 of pseudoephedrine amides, 
hydrolysis can be achieved in acidic or basic conditions. If the compounds are not acid-
sensitive, refluxing in a 1:1 mixture of concentrated sulfuric acid and dioxane will yield the 
corresponding carboxylic acid product. If these conditions are too harsh and decomposition or 
significant decrease in the product yield or optical purity occur, lower concentrations of 
sulfuric acid can be used, though longer times will be required (Figure 24).
46
 
 
 Figure 24: Acidic hydrolysis of pseudoephedrine amides
46
 
An alternative method for hydrolysis of acid-sensitive compounds was developed using a 
variety of hydroxide bases in different solvent systems. An example that was found optimal is 
using 5 equiv. of tetra-n-butylammonium hydroxide in a 1:4 mixture of t-butanol and water at 
reflux (Figure 25). In either cases of acidic or basic hydrolysis, the pseudoephedrine chiral 
auxiliary can be recovered by a simple extraction step during work-up.
46
 
 
 Figure 25: Basic hydrolysis of pseudoephedrine amides
46
 
Lewis acidic metal salts such as: ZnCl2, FeCl3, ZrOCl2 and Yb(OTf)3 were studied to develop 
another hydrolysis procedure using milder conditions. Increasing the ratio of water:dioxane 
solvent system from 1:1 to 4:1 lead to increasing the yield from an average of 90% to 94%. 
However, the long reaction times required in these types of metal-mediated reactions (48hrs) 
limit their use and encourage the search for other milder hydrolysis methods.
46 
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1.3.3 Chiral lithium amide bases 
In 2011, Stivala and Zakarian developed an alternative single-step method for asymmetric 
alkylation of arylacetic acid, first recognized by Shioiri and Koga more than a couple of 
decades ago. Instead of using a chiral auxiliary, they employed chiral lithium amides as non-
covalent stereodirecting agents. The alkylation reaction proceeds via enediolates 41a as 
reactive intermediates (Figure 26), which are of high nucleophilicity and limit the E/Z 
selectivity issues during enolization due to their geometrical symmetry. Several C2-symmetric 
tetramines were tested and the best enantioselectivity (93% ee, Figure 26) was achieved with a 
tetramine containing piperidine subunits and three-carbon linker (Figure 27). Optimum 
conditions used were 4.0 eq. of n-BuLi and slight excess (1.03 eq.) of chiral tetramine 42, 
which was recovered by extraction with aqueous HCl. It was found that enantioselectivity 
depended on the quality of n-BuLi, where lower % ee (52%) was observed when n-BuOLi, an 
impurity commonly found in aged n-BuLi bottles, was added to the reaction mixture. 
Moreover, methylation with more hindered alkyl halides, such as: isobutyl (98% ee), isopropyl 
(97% ee), and cyclopentyl iodides (96% ee), gave higher enantioselectivities compared to the 
smaller methyl iodide (88% ee), though they required longer reaction times.
55
 
 
 Figure 26: Direct asymmetric α-alkylation using chiral lithium amine.55 
 
Figure 27: Structure of C2-symmetric chiral tetramine.
55
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2 Aim of the study 
The aim of this study was to develop a synthetic route of enantiopure (R)-(-)-O-
desmethylangolensin. (R,R)-(-)-Pseudoephedrine was used as a chiral auxiliary, where the 
intermediate amide underwent stereoselective α-methylation. Figure 28 below outlines the 
synthetic route adopted in this work. 
All steps, along with the successes and limitations are discussed. MS, IR and NMR 
spectroscopy were used to follow the reaction series progress. 
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Figure 28: Synthetic route outline of (R)-(-)-O-DMA 
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3 Experimental Procedures 
3.1 General materials 
All EtOAc used in the work of this thesis was purchased from Sigma-Aldrich, DCM from 
Fisher Science, Et2O (anhydrous) from J.T. Baker, n-hexane from Merck and MeOH from 
VWR Prolabo Chemicals. TLC experiments were done on Silica gel on TLC Al foils (254 nm) 
from Sigma-Aldrich. All Na2SO4 (anhydrous) used was from Merck. For NMR analyses, 
acetone-d6 and CDCl3 used were purchased from Eurisotop. All dry THF was dispensed from 
VAC solvent purifier.  
3.2 Equipment 
The rotary evaporator used in all experiments was R-210 from Büchi. 
1
H and 
13
C NMR 
analyses were done using Oxford 300 MHz from Varian. EI-MS analyses were done using 
JEOL JMS-700 MStation. IR spectra were taken using ALPHA FT-IR Spectrometer from 
Bruker. Whenever the product is solid, the melting point was measured by a Büchi Melting 
Point B-545 instrument. The specific optical rotation measurements were performed using 
DIP-1000 Digital Polarimeter from JASCO. 
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3.3 Step 1 [249RH81] 
 
 Scheme 1: Step 1 (benzyl protection) 
3.3.1 Materials 
EtOH (99.5%) was purchased from Etax. 4-hydroxyphenylacetic acid 43 was purchased from 
TCI Europe and benzyl bromide was purchased from Fluka. NaI and KOH were purchased 
from Merck. Concentrated H2SO4 (95-97%) was purchased from J. T. Baker.  
3.3.2 Method 
4-Hydroxyphenylacetic acid 43 (6.00g, 1eq.), KOH (5.53g, 2.5eq.) and NaI (0.12g, cat.) were 
weighed into a dry 500ml 2-neck round-bottom flask. 99.5% EtOH (240ml) and BnBr 
(5.15ml, 1.1eq.) were then added. A stirring bar was added and a septum was used to close off 
one neck of the flask. A reflux condenser was attached to the other neck after being flushed 
with Ar and a CaCl2 tube put over the condenser. The mixture was left to reflux overnight in 
an oil bath while stirring. The next day, the reaction was monitored with TLC (7:2 
DCM:EtOAc) to make sure there was no starting material left. The flask was taken out of the 
oil bath and left to cool down. The reaction was stopped by evaporating to dryness with the 
rotary evaporator. White solid was formed, to which distilled water (240ml) was added and the 
pH was measured (pH=8) using a pH paper. Concentrated H2SO4 (95-97%) was added 
carefully till the pH became below 7 and a white solid was formed. The mixture was then 
filtered under vacuum using a Büchner filter and washed with distilled water. The white solid 
was left to dry under vacuum for a few hours, then was transferred to a dry 100ml round-
bottom flask to be dried in an oil pump for a few more hours and then overnight in the 
desiccator. Table 4 shows the % yields of step 1 trials performed. 
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Table 4: %Yields of step 1 trials  
Trial  % Yield 
1 [249RH49] 91.4 
2 [249RH81] 92 
 
44 [249RH81]:  
Yield after drying: 92%; white powder; melting point: 119-124 °C; 
1
H NMR (300 MHz, 
CDCl3) δ 7.419 (2H), 7.394 (1H), 7.361 (m, 2H), 7.205 (d, 2H, J = 9 Hz), 6.955 (d, 2H, J = 9 
Hz), 5.060 (s, 2H), 3.594 (s, 2H); 
13
C NMR (75 MHz, CDCl3) δ 178.290, 158.318, 137.156, 
130.647 (2C), 128.790 (2C), 128.170, 127.654 (2C), 125.805, 115.236 (2C), 70.254, 40.357; 
EI-MS m/z 242 ([M+H]
+
), 212, 196, 121, 106, 91; IR 2400-3300 (carboxylic acid OH str.), 
2905 (aliphatic CH str.), 1687 (acid C=O str.), 1510, 1244, 1012. 
3.4 Step 2 [249RH83] 
 
 Scheme 2: Step 2 (acid chloride formation) 
3.4.1 Materials 
Thionyl chloride was purchased from Sigma-Aldrich. Toluene was purchased from Lab Scan 
Analytical Sciences. Both were distilled in Ar atmosphere immediately before use.  
3.4.2 Method 
Product from step 1 [249RH81] 44 (5.03g, 1eq.) was weighed into a dry 100ml 2-neck round-
bottom flask with a magnetic stirrer and a rubber septum. Dry distilled toluene (75ml) was 
added to dissolve the solid under Ar atmosphere (using Ar balloon) and left in an ice bath to 
cool to 0 ºC. Dry distilled thionyl chloride (3.9ml, 1.28eq.) was then carefully added at 0 ºC 
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through the septum followed by attaching reflux condenser with CaCl2 tube after being 
flushed with Ar. The reaction mixture was allowed to reflux for 4-5 hours in an oil bath and 
the reaction was monitored using TLC (7:2 DCM:EtOAc) till there was no starting material, 
which was after about 4 hours. The reaction was stopped by removing the flask from the oil 
bath and left to cool to room temperature overnight. After a few days, the solution was 
evaporated to dryness using the rotary evaporator leaving a yellowish white solid. A sample 
was taken for MS analysis and the rest was continued further to the next step due to instability 
of the acyl chloride product. Table 5 shows the % yields of step 2 trials performed. 
Table 5: %Yields of step 2 trials  
Trial  % Yield 
1 [249RH43] 90.5 
2 [249RH45] 95.6 
3 [249RH55] 89.7 
4 [249RH83] 99.8 
 
45 [249RH83]:  
Yield after drying: 99%; yellowish white solid; EI-MS m/z 256, 197, 149, 106, 91; IR 3032 
(aromatic CH str.), 2908 (aliphatic CH str.), 1795 (acid chloride C=O str.), 1514, 1246.56, 
1012. 
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3.5 Step 3 [249RH85R] 
 
Scheme 3: Step 3 (attachment of pseudoephedrine chiral auxiliary) 
3.5.1 Materials 
(R,R)-(-)-Pseudoephedrine was purchased from Aldrich. Et3N was purchased from Merck, 
which was added to CaH2, left to dry overnight and distilled in Ar atmosphere immediately 
before use. CaH2 was purchased from Fluka.  
3.5.2 Method 
(R,R)-(-)-Pseudoephedrine (3.50g, 1eq.) was weighed into a dry 250ml 2-neck round-bottom 
flask with a magnetic stirrer and septum. The flask was closed off with an Ar balloon and the 
air was evacuated using an oil pump followed by flushing with Ar three times. Through the 
septum, dry THF (70ml) and dry distilled Et3N (3.5ml) were added. The flask was cooled to    
-78 ºC by putting it in dry ice/MeOH mixture. In another round-bottom flask, the acyl chloride 
product from the previous step [249RH83] 45 (5.4g, 1eq.) was dissolved in dry THF (35ml) 
and cooled in an ice bath. The acyl chloride solution was transferred to the reaction flask 
through the septum slowly over 45 min. while still keeping it at -78 ºC. The flask was then 
transferred to the freezer room and kept stirring over weekend. After a few days, the reaction 
was quenched by pouring the mixture into saturated NH4Cl (30ml). The product was extracted 
with DCM (3x30ml). In the first extraction step, the organic DCM layer was the upper layer, 
while in the second and third steps, it was the lower layer. The organic layers were combined 
and dried with Na2SO4 for 30 min, which was then filtered under vacuum and the filtrate was 
evaporated to dryness using the rotary evaporator, after which left to dry overnight. 
Flash chromatography (2:8 hexane:EtOAc) was used to purify the product. A 4cm-diameter 
column and 13cm long silica column were enough to separate the product, which eluted first. 
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After combining the eluted fractions and evaporating the solvent in the rotary evaporator, the 
product was recrystallized from toluene. A 10 mg/ml solution of 46 in MeOH was prepared to 
measure its specific optical rotation. 
46 [249RH85R]: 
Yield: 95% crude, 70% after recrystallization; light white crystals; melting point: 122-127 ºC; 
1
H NMR (300 MHz, CDCl3) δ 8.951 (s, 1H), 7.161-7.449 (m, 10 H), 7.093 (d, 2H, J = 8.1 
Hz), 6.922 (d, 2H, J = 7.8 Hz), 5.053 (s, 2H), 4.615 (d, 1H, J = 7.8 Hz), 4.435 (m, 1H), 3.626 
(s, 2H), 2.806 (s, 3H), 1.133 (d, 3H, J = 6.9 Hz); 
13
C NMR (75 MHz, CDCl3) δ 173.720, 
157.819, 142.480, 137.192, 129.990 (2C), 128.718 (2C), 128.511 (2C), 128.088 (2C), 
127.749, 127.607 (2C), 126.995, 126.531, 115.229 (2C), 58.882, 41.084, 33.535, 27.207, 
15.271, 14.503; IR 3100-3400 (small broad OH str.), 1608 (amide C=O str.), 1511, 1243, 
1043;     
   = -4.716º. 
3.6 Step 4 [249RH87R] 
 
 Scheme 4: Step 4 (asymmetric α-methylation) 
3.6.1 Materials 
n-BuLi and MeI were purchased from Sigma-Aldrich. LiCl and n-DIPA were purchased from 
Merck. 4-Biphenylmethanol 98% was purchased from Aldrich. 
3.6.2 Method 
First, n-BuLi was titrated in order to determine its actual molar concentration. 4- 
Biphenylmethanol was used as a titrating reagent. At least 80mg was weighed into a 10ml 2-
neck round-bottom flask with a magnetic stirrer and rubber septum. The flask was closed off 
with an Ar balloon and using an oil pump, air was evacuated and flask was flushed with Ar 
three times. The reagent was dissolved by adding dry THF (5ml) through the septum and 
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titration was done using 1ml syringe filled with n-BuLi. The concentration was calculated 
using this equation: 
      
             
                     
 
The titration was repeated three times and the average concentration was calculated, which 
turned out to be 1.41 M, from which the required volume was calculated. 
LDA (2.1eq.) was then prepared in-situ from n-DIPA and n-BuLi. A 50ml 2-neck round-
bottom flask with a magnetic stirrer, rubber septum and Ar balloon was connected to an oil 
pump. Air was evacuated and flask was flushed with Ar three times. Through the septum, n-
DIPA (2.5ml, 2.25eq.) and dry THF (20ml) were added. The mixture was cooled to -78 ºC by 
placing it in dry ice/MeOH. n-BuLi (11.5ml, 2.1eq.) was carefully added through the septum 
and the mixture was left to warm up to 0 ºC in an ice bath while continuing stirring for 30 min. 
For the asymmetric methylation, LiCl (2.00g, 6eq.) was weighed into a dry 250ml 2-neck 
round-bottom flask with a magnetic stirrer and rubber septum. The flask was closed off with 
Ar balloon and connected to an oil pump to evacuate air and flush the flask with Ar three 
times. Through the septum, dry THF (60ml) and the LDA previously prepared were added into 
the reaction flask under Ar. The mixture was cooled to -78 ºC by placing it in dry ice/MeOH. 
In a separate 100ml dry round-bottom flask, the pseudoephedrine amide product 46 from 
previous step [249RH85R] (3.00g, 1eq.) was weighed, dissolved in dry THF (10ml) in Ar 
atmosphere and cooled to 0 ºC. The amide solution was then added to the reaction mixture 
gradually over 30 min. at -78 ºC. Stirring was continued at -78 ºC for 1 hr., then for a further 
15 min. at 0 ºC. MeI (2ml, 4eq.) was added through the septum all at once and the mixture was 
left stirring in ice/water bath (0-4 ºC) overnight. 
The next day, the reaction was monitored by TLC (2:8 hexane:EtOAc), then quenched by 
pouring the mixture into 10% Na2CO3 (30ml). The product was extracted with DCM (3 x 
25ml). The organic layers were combined and dried with Na2SO4 for 30 min, which was then 
filtered under vacuum and the filtrate was evaporated to dryness using the rotary evaporator, 
after which left to dry over weekend. Flash chromatography (2:8 hexane:EtOAc) was used to 
purify the product. The eluted fractions were combined and solvent was evaporated to dryness 
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with the rotary evaporator leaving a light yellow oil, which was further dried with an oil pump. 
A 10 mg/ml solution of 47 in MeOH was prepared to measure its specific optical rotation. 
Table 6 shows the % yields of step 4 trials performed along with adjustments in reagents. 
Table 6: %Yields of step 4 trials 
Trial  % Yield MeI (eq.) LDA (eq.) 
1 [249RH61] 39.7 0.4 0.2 
2 [249RH87R] 70 4 2.1 
 
47 [249RH87R]: 
Yield: 105% crude, 70% after flash chromatography; light yellow sticky solid; melting point: 
98-108 ºC; 
1
H NMR (300 MHz, CDCl3) δ 7.311-7.418 (m, 10 H), 7.161 (d, 2H, J = 8.7 Hz), 
6.927 (d, 2H, J = 8.7 Hz), 5.043 (s, 2H), 4.575 (q, 1H, J = 7.8 Hz), 4.51 (d, 1H, broad), 4.448 
(m, 1H), 2.688 (s, 3H), 1.396 (d, 3H, J = 6.9 Hz), 1.120 (d, 3H, J = 6.9 Hz); 
13
C NMR (75 
MHz, CDCl3) δ 176.405, 157.907, 142.53, 137.193, 133.958, 128.937 (2C), 128.767 (2C), 
128.533 (2C), 128.157, 127.684 (2C), 127.003, 126.563 (2C), 115.446 (2C), 59.305, 43.578, 
33.221, 27.498, 20.992, 14.726, 14.304; EI-MS m/z 296, 238, 211, 148, 106, 91, 77;     
   = -
2.032º. 
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3.7 Step 5 [249RH93R] 
 
 Scheme 5: Step 5 (hydrolysis of pseudoephedrine chiral auxiliary) 
3.7.1 Materials 
Dioxane was purchased from Lab Scan Analytical Sciences. Concentrated H2SO4 was 
purchased from J. T. Baker. KOH was purchased from Merck. 
3.7.2 Method 
Methylated amide from the previous step 47 [249Rh87R] (0.90g) was weighed into a dry 
round-bottom flask and dissolved in dioxane (20ml). The solution was then added slowly to 
cooled 4M H2SO4 (20ml) in a dry 100ml 2-neck round-bottom flask with a rubber septum. A 
reflux condenser, which was previously flushed with Ar, with a CaCl2 tube was connected to 
the 2-neck reaction flask and the reaction mixture was left to reflux in an oil bath for a few 
hours. The reaction was monitored with TLC (2:8 hexane:EtOAc), which showed the reaction 
to be complete after 2.5hrs and the solution turned dark red brown in color. The flask was 
taken out of the oil bath and left to cool overnight. The next day, the mixture was poured into 
distilled water (30ml) and pH was adjusted to pH 12 with aq. KOH. The mixture was washed 
with EtOAc (3 x 20ml) to extract the released pseudoephedrine. The aqueous layer was then 
adjusted to pH below 3 with 4M H2SO4 and the product was extracted with DCM (5 x 20ml). 
The organic layers were combined and dried with Na2SO4 for 30 min, which was then filtered 
under vacuum and the filtrate was evaporated to dryness using the rotary evaporator, after 
which left to dry overnight.  
Flash chromatography (7:2 DCM:EtOAc) was first used to purify the product. The product did 
not come out of the column, and so switched the mobile phase to 7:2:2 DCM:EtOAc:acetic 
acid. The eluted fractions were combined and solvent was evaporated to dryness with the 
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rotary evaporator leaving a yellow oil, which was further dried with an oil pump. Table 7 
shows the % yields of step 5 trials performed. 
Table 7: %Yields of step 5 trials 
Trial  % Yield Notes 
1 [249RH67] 54 
No flash chromatography 
was done 
2 [249RH93R] 26.7  
 
48 [249RH93R]: 
Yield: 64% crude, 27% after flash chromatography; yellow oil; 
1
H NMR (300 MHz, acetone-
d6) δ 7.256 (2H), 7.164 (2H), 7.089 (1H), 7.023 (dd, 2H, J = 2.4 Hz, 8.6 Hz), 6.787 (d, 2H, J 
= 8.6 Hz), 3.959 (s, 2H), 3.645 (q, 1H, J = 6.6 Hz), 1.39 (d, 3H, J = 6.6 Hz); 
13
C NMR (75 
MHz, acetone-d6) δ 176.35, 157.56, 133.29, 130.92 (2C), 129.91 (2C), 129.58 (2C), 129.25, 
127.28, 126.76, 116.36 (2C), 45.25, 19.49. 
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3.8 Step 6 [249RH95R] 
 
 Scheme 6: Step 6 (O-DMA synthesis by Friedel-Crafts acylation) 
3.8.1 Materials 
Resorcinol and BF3.Et2O (purified by redistillation, ≥46.5% BF3 basis) were purchased from 
Sigma-Aldrich. NaHCO3 was purchased from Merck. 
3.8.2 Method 
Resorcinol (0.134g, 2.02eq.) was weighed into a dry 25ml 2-neck round-bottom flask with a 
magnetic stirrer and rubber septum. A reflux condenser with an Ar balloon was connected and 
closed off the flask. Using an oil pump, air was evacuated and Ar was introduced three times. 
In another dry round-bottom flask, the R-acid from the previous step [249RH93R] 42 (154mg, 
1eq.) was dissolved in minimum amount of Et2O and added through the septum into the 
reaction flask under Ar. Then, BF3.Et2O (0.23ml, 3.05eq.) was added through the septum and 
the reaction was allowed to reflux in an oil bath at 120 ºC for 15 min. the flask was taken out 
of the oil bath and left to cool to room temperature. 10% NaHCO3 (10ml) was added to quench 
the reaction followed by extraction with Et2O (3 x 10ml). The organic layers were combined, 
washed with distilled water (10ml), then brine (10ml) and dried with Na2SO4 for 30 min, 
which was then filtered under vacuum and the filtrate was evaporated to dryness using the 
rotary evaporator, after which left to dry overnight. TLC (7:2 DCM:EtOAc) was done to make 
sure the reaction was complete and check the solvent system to be used for flash 
chromatography to purify the product. A 2.5cm diameter column and 20cm layer silica were 
used. The eluted fractions were combined and solvent was evaporated to dryness with the 
rotary evaporator leaving a brown oil, which was further dried with an oil pump. After leaving 
it to dry overnight, a brown solid was formed. A 10 mg/ml solution of 4a in MeOH was 
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prepared to measure its specific optical rotation. Table 8 shows the % yields of step 6 trials 
performed. 
Table 8: %Yields of step 6 trials 
Trial  % Yield Notes 
1 [249RH75] 13 
Reaction was done at 70ºC 
overnight 
2 [249RH95R] 55 
Reaction was done at 
120ºC for 15 min. 
 
4a [249H95R]: 
Yield: 183% crude, 55% after flash chromatography; brown solid; melting point: 127-133 ºC 
(lit.
23
: 139-140 ºC); 
1
H NMR (300 MHz, acetone-d6) δ 12.889 (s, 1H), 9.383 (s, 1H), 8.229 (s, 
1H), 7.908 (d, 1H, J = 9 Hz), 7.207 (d, 2H, J = 8.4 Hz), 6.785 (d, 2H, J = 8.7 Hz), 6.360 (dd, 
1H, J = 8.7Hz, 2.4Hz) 6.300 (d, 1H, J = 2.4Hz), 4.778 (q, 1H, J = 6.8 Hz), 1.437 (d, 3H, J = 
6.9 Hz); 
13
C NMR (75 MHz, acetone-d6) δ 205.500, 166.315, 164.704, 156.556, 133.386, 
133.082, 128.797 (2C), 115.837 (2C), 112.427, 107.987, 103.019, 45.556, 18.878; EI-MS m/z 
258 ([M+H]
+
), 137, 121, 91, 77;     
   = -6.112º (lit.
7
: -135.8 º). 
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4 Results and discussion 
4.1 General  
The main purpose of this work was to develop a stereoselective synthetic route of enantiopure 
(R)-(-)-O-DMA. As explained previously, the chirality is present at C-2, thus the suggestion of 
starting from the precursor 4-hydroxyphenylacetic acid 43 (Figure 29), which would undergo 
asymmetric methylation at the α-carbon to give the (R)-2-(4-hydroxyphenyl)propionic acid 
followed by Friedel Craft acylation with resorcinol. Alkylation can be achieved using enolate 
chemistry taking advantage of the neighboring carbonyl functional group, while using a chiral 
auxiliary to obtain the desired stereochemistry. Since pseudoephedrine amides proved to be 
excellent substrates for these types of alkylation reactions as well as their ease of hydrolysis, 
(R,R)-(-)-Pseudoephedrine was chosen as a suitable chiral auxiliary. Scheme 7 depicts the full 
reaction series of this multistep synthesis.  
 
Figure 29: Structures of (R)-(-)-O-DMA and 4-hydroxyphenylacetic acid 
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 Scheme 7: Synthetic route outline of (R)-(-)-O-DMA 
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4.2 Step 1  
 
 Scheme 1: Step 1 (benzyl protection) 
To avoid unwanted side reactions or products, firstly the aromatic hydroxyl group should be 
protected. Benzyl protection was employed using benzyl bromide in basic conditions. The 
reaction was straightforward giving a pure white powder with a yield of over 90%. EI-MS 
showed the expected molecular ion peak at m/z 242 (See Appendix 3). 
1
H and 
13
C NMR 
spectra also confirmed the presence of the desired product 38 (See Appendix 1 and 2). 
4.3 Step 2 
 
 Scheme 2: Step 2 (acid chloride formation) 
In order to attach the pseudoephedrine chiral auxiliary, the carboxylic acid group should 
initially be activated. In this case, it was converted to acid chloride by refluxing with thionyl 
chloride in toluene. An important precaution in this reaction is that all equipment and solvents 
have to be completely dry, thus thionyl chloride and toluene were distilled immediately before 
use and kept under inert Ar atmosphere. In earlier attempts, the solution color turned dark red 
during reflux and TLC showed many impurities. It was assumed the reason was the presence 
of some moisture, therefore when repeating extra caution was held to avoid any contact with 
air and moisture during distillation and setting up of the reaction. TLC showed much better 
purity and the color was yellow to orange. 
The acid chloride product is extremely moisture and air sensitive, so the next reaction should 
proceed afterwards directly. If not possible, the reaction mixture was left in solution and 
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evaporated to dryness only before carrying on further. Also, it is not feasible to prepare 
samples for NMR analysis due to product instability. However, a small sample was taken for 
IR and EI-MS analysis to make sure the reaction was successful (See Appendix 5 and 6). IR 
spectrum showed no sign of the broad peak characteristic for carboxylic acid OH group and 
only showed the sharp peak caused by the carbonyl group at 1800 cm
-1
 (See Appendix 6).  
4.4 Step 3 
 
Scheme 3: Step 3 (attachment of pseudoephedrine chiral auxiliary) 
After benzyl protection of phenolic hydroxyl group and activation of the carboxylic acid group 
into an acid chloride, the pseudoephedrine chiral auxiliary can be attached. According to 
literature, stereoselective α-alkylation of pseudoephedrine amides occurs on the same side as 
the pseudoephedrine methyl group
24
; and so the (R,R)-(-) enantiomer was selected to finally 
yield the pure (R)-O-DMA isomer. Formation of the amide was done using triethylamine as 
base in THF as solvent. Similar to the previous reaction, moisture should be eliminated; hence 
triethylamine was left on CaH2 overnight, distilled immediately before use and covered with 
anhydrous CaCl2 tube. Also, THF was dispensed from a solvent purifier machine just prior use 
and kept under inert Ar atmosphere to ensure the absence of any moisture. 
As expected, the acylation reaction occurred readily with a small amount of impurity that is 
easily removed by flash chromatography. The product is easily recrystallized from toluene and 
a relatively high yield of 70% of white fluffy crystals was obtained after flash chromatography 
and recrystallization. The crystals are moisture and air-stable, thus could be conveniently 
stored in a closed container in the fridge for long-term use. 
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4.5 Step 4  
 
 Scheme 4: Step 4 (asymmetric α-methylation) 
Afterwards comes the most important and main objective of this work, which is the 
asymmetric methylation of the α-carbon. The pseudoephedrine amide enolate was formed by 
the reverse addition of the amide to an excess amount of base, LDA, which was prepared in-
situ, followed by addition of excess alkylating agent, which is methyl iodide in this case. LiCl 
was added to the LDA suspension to accelerate the reaction as stated in previous studies.
24
  
Initially, the reaction failed; where the TLC revealed only the starting material along with 
many impurities. Also, 
1
H NMR spectrum did not show the expected peak for the presumably 
added methyl group. After further research, it was believed that the presence of some moisture 
in THF could be the explanation. When repeating, extra care was taken by keeping all solvents 
and chemicals under inert Ar atmosphere at all times, especially when dispensing the THF 
from the solvent purifier. To keep the THF dry, the collecting flask was closed off with an Ar 
balloon and the required amount was withdrawn through the septum with a syringe. Only then, 
the reaction was successful; TLC showed an additional spot and an extra doublet peak at 
around 1.4 ppm appeared in the 
1
H NMR spectrum as expected (See Appendix 11). However, 
there were still a lot of impurities and unreacted amide, which decreased the yield to less than 
40% after flash chromatography. 
In an effort to increase the yield and purity, the amounts of LDA, LiCl and MeI used were 
adjusted to 2.1 eq., 6 equiv. and 4 equiv. respectively (refer to Table 6). The reaction was 
repeated with larger amount of starting material (3g instead of 1g), while the procedure and all 
other aspects remained unchanged. TLC showed much less impurities and a larger product 
yield; and indeed after flash chromatography, the yield was found to be 70%.  
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All trials of the reaction yielded an oily product, which when completely dry became a sticky 
solid/semisolid. This made any attempt to recrystallize the product very hard to achieve. 
Although the reaction was a success, nevertheless the broad melting point range and unwanted 
peaks in the NMR spectra indicate residual impurities. Perhaps, this could be the reason for 
not getting a solid product and failure to recrystallize. Also, as per literatre
55
, the quality of n-
BuLi affects the enantioselectivity and possibly the yield as well, therefore this could also be 
another reason for the presence of impurities and the low enantioselectivity of the added 
methyl group. 
4.6 Step 5  
 
 Scheme 5: Step 5 (hydrolysis of pseudoephedrine chiral auxiliary) 
Hydrolysis of the amide and release of the pseudoephedrine to give enantiopure (R)-acid 42 
was done by acidic hydrolysis in 1:1 mixture of dioxane:H2SO4. It was noticed that the color 
always turns dark orange/red during reflux. Evaporating the solvent to dryness leaves off dark 
red oil, which contains many impurities shown in the TLC and 
1
H NMR spectrum. 
Recrystallization failed and was not sufficient to remove the impurities. Flash chromatography 
was necessary to purify the product enough to proceed with the next reaction. However, this 
caused a significant loss of the product (yield: 27%), yet still left with yellow oil, lighter in 
color. It might possibly be that this method of hydrolysis could be too harsh causing some side 
reactions giving unwanted byproducts and decreasing the yield. Other milder procedures, such 
as: basic hydrolysis or using Lewis acidic metal salts, should be studied to find an alternative 
approach to release the pseudoephedrine with higher purity and yield. Though, it should be 
kept in mind the product stability, cost and reaction time.  
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4.7 Step 6  
 
 Scheme 6: Step 6 (O-DMA synthesis by Friedel-Crafts acylation) 
The final reaction in this multistep synthesis can be proceeded, which is Friedel-Crafts 
acylation of 42 with resorcinol in BF3.Et2O, similar to racemic O-DMA synthesis as explained 
in literature.
21-23
 The same protocol and conditions were employed; however the final yield 
after flash chromatography was merely 55% (literature recorded at least 80%
21-23
). This could 
be due to the presence of residual impurities from previous steps. It should also be noted that 
purification by flash chromatography was rather difficult; the impurities eluted very close to 
the product and some loss was inevitable in order to get pure O-DMA. This was observed in 
racemic O-DMA synthesis as well, though a considerably higher yield was obtained (91%), 
which is comparable to previous references.  
EI-MS showed the expected molecular ion peak at m/z 258 alongside with typical O-DMA 
fragment ion peaks (See Appendix 18).
8
 Also, both 
1
H and 
13
C NMR spectra exhibited results 
identical to racemic O-DMA synthesized by Friedel-Crafts acylation as well as those found in 
literature (See Appendix 16 and 17).
8
 The measured     
   was found to have a negative value 
(-6.112º) as expected, which proves the (R)-(-) optical nature of the synthesized O-DMA. 
However, by comparing to the value published in literature (    
   = -135.8º)
7
, %ee was 
calculated to be 4.5%. The equation     
                 
  
             
       was used to calculate the 
%ee. Attempts to recrystallize the product from 1:1 Et2O:n-hexane were not successful; rate of 
recrystallization was too rapid and pale yellow amorphous crystals were formed, which are not 
suitable for X-ray crystallography. Similar trials on racemic O-DMA also failed. Alternative 
solvents/solvent mixtures for recrystallization should be further studied and larger amounts of 
product should be available for better and more reproducible results. 
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5 Conclusion 
O-Desmethylangolensin has been and still is studied extensively with respect to its biological 
activities and potential health benefits. Since recently, it has been identified that (R)-(-)-O-
DMA is the major enantiomeric form produced by intestinal bacteria
7
, hence it would be 
useful to develop an organic synthetic route to synthesize this O-DMA enantiomer in a chiral 
fashion, which was the main purpose of this work. (R,R)-(-)-Pseudoephedrine was used as a 
chiral auxiliary for subsequent diastereoselective α-methylation. The proposed method was 
found to be successful; (R)-(-)-O-DMA was eventually produced, yet the %ee was very low. 
As mentioned in literature, the pseudoephedrine amide was easily formed yielding in pure 
stable white crystals. However, there were several difficulties concerning the α-methylation 
step; most importantly the success of the reaction depended on the complete absence of 
moisture and avoiding its introduction. Moreover, recrystallization of the final product should 
be investigated further in order to perform X-ray crystallography experiments, which would 
give a clearer and more precise idea about the stereochemistry and enantioselectivity. 
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